Orexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactions
· All four investigational formulations of OX640 were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine · Data available today indicates significantly improved stability compared to current standard of care in a broad range of temperatures · Targeted epinephrine market for auto-injectors exceeds USD 2 billion and expects to show an annual growth of 8-9 percent[1] · Partnership strategies evaluated for continued development and commercialization Uppsala, Sweden – October 11, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today